KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Non-Current Debt (2016)

Vertex Pharmaceuticals has reported Non-Current Debt over the past 5 years, most recently at $74.9 million for Q2 2016.

  • Quarterly results put Non-Current Debt at $74.9 million for Q2 2016, down 70.26% from a year ago — trailing twelve months through Jun 2016 was $74.9 million (down 70.26% YoY), and the annual figure for FY2015 was $223.9 million, down 20.21%.
  • Non-Current Debt for Q2 2016 was $74.9 million at Vertex Pharmaceuticals, down from $149.6 million in the prior quarter.
  • Over the last five years, Non-Current Debt for VRTX hit a ceiling of $294.8 million in Q3 2015 and a floor of $74.9 million in Q2 2016.
  • Median Non-Current Debt over the past 3 years was $259.1 million (2015), compared with a mean of $229.6 million.
  • Biggest five-year swings in Non-Current Debt: rose 0.03% in 2015 and later crashed 70.26% in 2016.
  • Vertex Pharmaceuticals' Non-Current Debt stood at $280.6 million in 2014, then decreased by 20.21% to $223.9 million in 2015, then crashed by 66.53% to $74.9 million in 2016.
  • The last three reported values for Non-Current Debt were $74.9 million (Q2 2016), $149.6 million (Q1 2016), and $223.9 million (Q4 2015) per Business Quant data.